Mindray Medical Announces Preliminary 2009 Operating Results
For the year ended
Based on the estimated full year revenue, the company anticipates the 2009 non-GAAP diluted EPS to be no less than
"2009 was a year in which many companies experienced economic crisis and broad uncertainties," commented Mr.
"As we closed the fourth quarter of 2009, we saw strong business growth in
Mindray's preliminary 2009 results are unaudited and remain subject to the finalization of the company's year-end closing, reporting and audit processes. 2010 full-year guidance will be provided in the fourth quarter and 2009 year- end earnings announcement.
About Mindray
We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Mindray's anticipated net revenues and earnings per share for 2009, growth of market share in 2010, growth of net revenues in 2010, growth of market share and new market penetration, expansion of our presence in emerging markets, improving our developed market sales capabilities and improving the effectiveness of our working capital utilization, and the release of new products are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. The anticipated results for 2009 remain subject to the finalization of Mindray's year-end closing, reporting, and audit processes, particularly as related to accrued expenses, income taxes, share- based compensation expenses, and expense and/or amortization of intangible assets. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F, filed on
Use of Non-GAAP Financial Measures
The company has announced its expected diluted earnings per share for full year 2009 on a non-GAAP basis which is being used in the consistent method from period to period.
Because the financial performance is subject to finalization of the company's year-end closing, reporting, and audit processes, the company does not provide a specific non-GAAP to US GAAP reconciliation. A reconciliation of non-GAAP results of operations measures to the nearest comparable GAAP measures will be provided with the company's audited financial results and adjusted for the effects of share-based compensation, amortization of acquired intangible assets, realignment cost-post acquisition and termination payment, as well as any one-time non-operating income/ charge, all of which are net of related tax impact and dividend by diluted weighted shares outstanding for the year.
For investor and media inquiries please contact: In the U.S.: Evan Smith, CFA FD Tel: +1-212-850-5606 Email: [email protected] John Capodanno FD Tel: +1-212-850-5705 Email: [email protected] In China: May Li Mindray Investor Relations Tel: +86-755-2658-2518 Email: [email protected]
SOURCE Mindray Medical International Limited
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article